Kayikci, OmurMehtap, OzgurSari, IsmailDemirkan, FatihBeyan, CengizCetin, GuvenVural, Filiz2023-01-122023-01-1220221300-77771308-5263https://doi.org/10.4274/tjh.galenos.2022.2022.0052https://hdl.handle.net/11454/78787Objective: Peripheral T-cell lymphomas (PTCLs) are an uncommon and quite heterogeneous group of disorders, representing only 10%-15% of all non-Hodgkin lymphomas. Although both molecular and clinical studies have increased in recent years, we still have little knowledge regarding real-life practice with PTCLs. In this study, we aimed to investigate the clinical characteristics and treatment outcomes of a large population-based cohort of patients presenting with systemic non-cutaneous PTCL. Materials and Methods: We conducted a multicenter retrospective analysis of 190 patients consecutively diagnosed and treated with non-cutaneous PTCLs between 2008 and 2016. Results: Considering all first-line treatment combinations, the overall response rate was 65.9% with 49.4% complete remission (n=81) and 16.5% partial response (n=27). The 5-year overall survival and event-free survival rates were significantly different between the transplant and non-transplant groups (p<0.01, and p=0.033, respectively). Conclusion: The retrospective analysis of a large volume of real-life data on the Turkish experience regarding non-cutaneous PTCL patients showed consistent results compared to other unselected PTCL cohorts with some minor differences in terms of survival and transplantation outcomes. The long-term outcome of patients who receive autologous hematopoietic cell transplantation as part of upfront consolidation or salvage therapy is favorable compared to patients who are unable to receive high-dose therapy.en10.4274/tjh.galenos.2022.2022.0052info:eu-repo/semantics/openAccessLymphomasAutologous stem cell transplantationT-cell lymphomasNon-Hodgkin lymphomaHigh-Dose ChemotherapyAmerican SocietyUp-FrontTransplantationSurvivalGuidelinesPrognosisDiseaseCohortArticle393170177WOS:0008834738000032-s2.0-8513700043135678126Q3Q3